Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era.

EJHaem · 2026 · PMC13240352 · PMID 42253631

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Patients with CR/PR prior to alloHCT showed a trend toward superior 3‐year OS compared to those with SD/PD (50% [95% CI: 32%–78%] vs. 22% [95% CI: 7%–75%]; HR: 2.35, 95% CI: 0.95–5.81; p = 0.06).

also in 53,322 other papers

a clear trendno p-value reported

However, a clear trend toward inferior outcomes in patients with PD/SD was observed, supporting the clinical relevance of disease control prior to transplantation.

also in 19,460 other papers

did not reach statistical significanceno p-value reported

In our cohort, this association did not reach statistical significance, most likely due to the limited sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.